Teva Copaxone Patent Maintained in Europe; Still Under Challenge in U.S.

Jenny David

首页> 外文期刊>World intellectual property report >Teva Copaxone Patent Maintained in Europe; Still Under Challenge in U.S.

【24h】

Teva Copaxone Patent Maintained in Europe; Still Under Challenge in U.S.

机译：Teva Copaxone专利在欧洲拥有；在美国仍然面临挑战

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Teva Pharmaceuticals and Mylan Inc. announced Nov. 25 that they have reached a settlement under which pending patent litigation will be discontinued in France, the Netherlands and the United Kingdom. The suits relate to the impending expiration of Teva's patents on its flagship multiple sclerosis (MS) treatment Copaxone, and are part of the Israel-based company's global efforts to maintain exclusivity on the drug's international sales through 2015. Teva also faces legal challenges in the United States from rival companies that have developed generics versions of the drug, including Mylan.

机译：Teva Pharmaceuticals和Mylan Inc.于11月25日宣布，他们已经达成和解，根据该和解，在法国，荷兰和英国将终止正在审理的专利诉讼。这些诉讼与Teva旗舰多发性硬化（MS）治疗药Copaxone的专利即将到期有关，这是这家以色列公司在全球范围内努力维持该药物在2015年之前的国际销售权的一部分。Teva还面临着法律挑战。美国来自开发了仿制药版本的竞争对手公司，包括Mylan。

著录项

来源
《World intellectual property report》 |2014年第1期|19-19|共1页
作者
Jenny David;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Teva Stock Price Plunges After PTAB Invalidates Two U.S. Copaxone Patents [J] . Susan Decker, Catherine Larkin World intellectual property report . 2016,第9期

机译：PTAB使两项美国Copaxone专利无效后，Teva股票价格暴跌
2. Teva's Copaxone UK Dosage Patent Invalid as Mylan Preps Generic [J] . Peter Leung World intellectual property report . 2017,第11期

机译：Teva的Copaxone UK剂量专利无效，因为Mylan Preps通用
3. Teva's patent plea on 'Copaxone' rejected in US: Natco [J] . Chemical Weekly Group Chemical Weekly . 2014,第36期

机译：梯瓦公司关于“可可松”的专利请求在美国被拒绝：纳特科
4. THE PATENT SYSTEM: CURRENT AND FUTURE POLICY CHALLENGES A VIEW FROM THE EUROPEAN PATENT OFFICE [C] . Manuel Desantes, Organisation for Economic Co-operation and Development(OECD) OECD Conference on Intellectual Property Right, Innovation and Economic Performance . 2004

机译：专利制度：当前和未来的政策挑战欧洲专利局的观点
5. A Comparative Study on Human Embryonic Stem Cell Patent Law in the United States, the European Patent Organization, and China. [D] . Zhu, Huan. 2011

机译：美国，欧洲专利组织和中国的人类胚胎干细胞专利法比较研究。
6. Analytical Challenges and Regulatory Requirements for Nasal Drug Products in Europe and the U.S. [O] . Sabrina Trows, Klaus Wuchner, Rene Spycher, 2014

机译：欧洲和美国鼻用药物产品的分析挑战和法规要求
7. "Patent Protection in Europe and Its Significance for the Countries of the Euro-Mediterranean Area." In EURO-MED INTEGRATION AND THE 'RING OF FRIENDS': THE MEDITERRANEAN'S EUROPEAN CHALLENGE, VOL. IV" [O] . Ilgaz Deniz. 2003

机译：“欧洲的专利保护及其对欧洲 - 地中海地区国家的意义”。在EURO-mED集成和'朋友圈'中：地中海的欧洲挑战，VOL。 IV”

Teva Copaxone Patent Maintained in Europe; Still Under Challenge in U.S.

摘要

著录项

相似文献

相关主题

期刊订阅